Adam Hacker, a former executive at Janssen Pharmaceuticals, has joined Autolus Therapeutics Plc as senior vice president for regulatory affairs and quality to help guide development of the company’s T cell therapies for cancer. At Janssen, Dr Hacker was responsible for leading regulatory activities relating to the microbiome, regenerative medicines and digital technology.
Prior to this, he was head of oncology, immunology and cardiovascular therapeutic areas at Biogen Idec Ltd. He obtained a PhD in developmental molecular biology from the National Institute of Medical Research in London, UK.
Autolus announced the appointment on 17 October 2018.
Copyright 2018 Evernow Publishing Ltd